IpIBA seminar series 2022/2023“Exploiting nanobodies targeting ABCC3 for glioblastoma immunoguided applications.”

Tuesday, November 29th 2022 From 9:30 to 10:30

Glioblastoma is the most aggressive primary brain tumor in adults. Efficiency of current diagnostic methods and therapeutic strategies of glioblastoma is narrowed by the presence of the molecular-restrictive blood-brain barrier (BBB), and the belated translation of relevant biomarkers into the clinical practice. New efforts emerge towards a personalized medicine, based on molecularly matched formulations against specific tumor biomarkers of this heterogeneous tumor. Due to their molecular features, nanobodies emerge as novel promising immunotargeted tools for glioblastoma.

Place:

CIBA, main meeting room, and online via zoom

Importante las plazas son limitadas: 100 presencial y 100 modalidad on line. Si participa de forma presencial no hace falta realizar inscripción on line.